Graphical Abstract Highlights d A 3-parameter model compactly captures the kinetic features of dual phosphorylation d ERK dual phosphorylation by wild-type MEK is partially processive in vitro d MEK E203K, a cancer mutation, increases the processivity of ERK phosphorylation d MEK Y130C and F53S mutations increase the rate of MEK activation
In Brief
Yeung et al. apply Bayesian parameter inference to a structurally identifiable kinetic model to dissect the dual phosphorylation of ERK by MEK, a kinase that is mutated in a large number of human diseases. They find that enzyme processivity and the catalytic efficiencies of individual phosphorylation steps can be altered by pathogenic mutations.
SUMMARY
Multisite protein phosphorylation plays a critical role in cell regulation [1] [2] [3] . It is widely appreciated that the functional capabilities of multisite phosphorylation depend on the order and kinetics of phosphorylation steps, but kinetic aspects of multisite phosphorylation remain poorly understood [4] [5] [6] . Here, we focus on what appears to be the simplest scenario, when a protein is phosphorylated on only two sites in a strict, well-defined order. This scenario describes the activation of ERK, a highly conserved cell-signaling enzyme. We use Bayesian parameter inference in a structurally identifiable kinetic model to dissect dual phosphorylation of ERK by MEK, a kinase that is mutated in a large number of human diseases [7] [8] [9] [10] [11] [12] . Our results reveal how enzyme processivity and efficiencies of individual phosphorylation steps are altered by pathogenic mutations. The presented approach, which connects specific mutations to kinetic parameters of multisite phosphorylation mechanisms, provides a systematic framework for closing the gap between studies with purified enzymes and their effects in the living organism.
RESULTS AND DISCUSSION
Multisite protein phosphorylation plays a critical role in signaling cascades regulating key cellular events, including the cell cycle and circadian rhythms [1] [2] [3] . Functional capabilities of multisite phosphorylation reactions depend on the order and kinetics of different phosphorylation steps [13, 14] . Nevertheless, quantitative understanding of multisite phosphorylation kinetics remains elusive, even for the best studied examples [4] [5] [6] . This is largely due to the combinatorial complexity of multisite phosphorylation. Indeed, a protein with n phosphorylation sites can be found in 2 n possible phosphostates, which may be connected by n! alternative pathways [15] . Here, we focus on what appears to be the simplest multisite case, when a protein is phosphorylated on only two sites and when the unphosphorylated and dually phosphorylated forms are connected by an ordered mechanism. Simple as it is, this case corresponds to the activation of the extracellular signal regulated kinase (ERK), a highly conserved signaling enzyme in metazoans [16] .
ERK is activated when it is dually phosphorylated by MEK, a kinase that phosphorylates first the tyrosine and then the threonine within the TEY sequence in the regulatory loop of ERK [17] . Upon activation, ERK phosphorylates a broad spectrum of substrates, including regulators of the cell cycle, cytoskeleton, and transcription. Mutations affecting either MEK or ERK are commonly associated with diseases, most notably cancers and developmental defects [12] [13] [14] [15] [16] [17] . As a consequence, processes leading to ERK activation, such as ERK phosphorylation by MEK or phosphorylation and activation of MEK itself, serve as successful drug targets in oncology [18] . While multiple mutations in MEK are known to affect the overall levels of dually phosphorylated ERK in vivo, their effects on the mechanism of ERK activation remain unknown [19] [20] [21] [22] [23] . Here, we address this question using kinetic studies and Bayesian parameter inference.
Our approach relies on transient kinetic analysis of ERK phosphorylation by MEK, using phostag gels to separate the unphosphorylated (S 0 ), monophosphorylated (S 1 ), and dually phosphorylated (S 2 ) forms of ERK ( Figures 1A and 1B) [24, 25] . Kinetic data were analyzed via a mathematical model that describes ordered dual phosphorylation ( Figure 1C ). This is consistent with previous kinetic and structural studies showing that the tyrosine is phosphorylated before the threonine [26] . The species of this model correspond to the three phosphostates of ERK (S 0 -unphosphorylated ERK, S 1 -ERK phosphorylated on tyrosine, and S 2 -dually phosphorylated ERK), free enzyme (E), and two enzyme-substrate complexes (ES 0 and ES 1 ). The complex of MEK with monophosphorylated ERK can either dissociate or continue to dually phosphorylated product. Thus, this model contains both distributive and processive pathways, in which the two phosphorylations are carried out by either two separate enzyme molecules or the same molecule, respectively.
With two sets of association, dissociation, and catalysis rate constants for two sequential phosphorylations, the model has six parameters. We established that this model is structurally identifiable: given enough measurements, the values of these parameters can be identified from kinetic data (see Supplemental Information). In practice, however, identifying parameters is extremely challenging, due to measurement noise and differences in the timescales of individual reactions [27, 28] . As a consequence, parameter estimation commonly leads to ensembles of parameters that are equivalent in describing the data but are not readily suitable for mechanistic interpretation of the underlying dynamics. We ran into this challenge when we attempted to identify the six parameters of our model ( Figure S2A ).
We noticed, however, that the ratio of total substrate to the Michaelis constant ðK M = ½k r + k cat =k f Þ for each phosphorylation was below 1 ( Figure S2B ), indicating that we were not using a saturating substrate concentration. This observation agrees with previous biophysical measurements of MEK/ERK interactions in vitro that established that MEK and ERK bind with $25 mM affinity, which is indeed greater than the maximal substrate concentration used in our experiments (5 mM) [29] . In this regime, the free enzyme concentration can be considered constant and equal to the total enzyme concentration (see Supplemental Information). This justifies model reduction and leads to a simpler model with only three effective parameters ( Figure 2A) : ; p = k cat;2 k cat;2 + k r;2 :
The first two parameters are products of enzyme concentration, which is controlled by experimental design, and kinetic efficiencies ðk cat;1ð2Þ =K M;1ð2Þ Þ of the first and second phosphorylations. The third parameter can be interpreted as the probability that both phosphorylations are carried out by the same enzyme molecule, without an intervening dissociation step. This is a measure of processivity: the p = 0 limit corresponds to the fully distributive regime, when monophosphorylated ERK necessarily dissociates from MEK following the first phosphorylation step. When p = 1, monophosphorylated ERK remains associated with MEK and proceeds directly to the second phosphorylation step.
While the full model is nonlinear and must be solved numerically, the reduced model is linear and can be solved analytically, leading to compact expressions for the time-dependent concentrations of the three ERK phosphostates: S 0 ðtÞ = S tot e Àk 1 t ; S 1 ðtÞ = S tot k 1 ð1 À pÞ k 1 À k 2 À e Àk 2 t À e Àk 1 t Á ;
S 2 ðtÞ = S tot À S 0 ðtÞ À S 1 ðtÞ;
where S tot is the total substrate concentration. The reduced model is also structurally identifiable (see Supplemental Information). Based on this result, we used a Bayesian approach to parameter inference. This approach naturally accounts for measurement noise and yields a posterior distribution of parameters instead of their point or interval estimates [30] . We performed Bayesian inference of the three model parameters assuming a broad prior and used Markov Chain Monte Carlo methods to sample from the posterior distribution (see Supplemental Information). As a result, the kinetic data gave rise to a sample from the posterior distribution in the three-dimensional parameter space ( Figures 2B and S1A ). This approach is readily applicable for inferring kinetic parameters of mutants that are used in basic research or are associated with diseases ( Figure 3A ). In particular, the first phosphorylation step is commonly studied using ERK in which the threonine for the second phosphorylation is changed to alanine [33]. When we performed our analysis with this ERK mutant, we observed that the kinetic efficiency of the first phosphorylation is $3 times higher when the second phosphorylation site is disrupted ( Figure S1 ). This highlights the importance of working with the wild-type ERK to obtain biologically relevant rate constants. Furthermore, multiple studies have used phosphomimetic MEK variants rather than the wild-type MEK activated by Raf [33] [34] [35] [36] [37] [38] . In one of these variants (S218D, S222D), the two serines in the activation loop are changed to aspartates, mimicking the negative charge introduced by phosphorylation [33, 39]. This variant is known to be less active than phosphorylated MEK, but its use simplifies experimental design. Indeed, when we repeated our Bayesian analysis of kinetic data obtained using this phosphomimetic MEK ( Figure S4 ), we found that kinetic specificities for both phosphorylation steps are significantly lower than those for the dually phosphorylated wild-type MEK ( Figure 3C ). However, the processivities of the wild-type and phosphomimetic enzymes are essentially the same and significantly greater than zero, indicating that $1/3 of ERK molecules are dually phosphorylated in a single enzyme substrate encounter. This result can be understood by examining the definitions of k 1 , k 2 , and p. By decreasing the rate at which MEK binds to unphosphorylated and monophosphorylated ERK, the SSDD mutation could decrease the catalytic efficiencies of both phosphorylations while keeping the processivity constant.
Next, we analyzed the kinetic parameters of three MEK variants associated with human diseases. Each of these variants is characterized by a single amino acid substitution that disrupts the intramolecular contacts with the N-terminal negative regulatory region of MEK ( Figure 3A ) [31, 40] . In parallel with the phosphorylation of serines within the activation loop, this region provides allosteric control of MEK activation. The E203K variant was identified in a human cancer, while the F53S and Y130C variants were found in humans with a broad spectrum of developmental abnormalities, including congenital heart defects and stunted growth [12, 41] . Studies in fly and fish Table S1 and Figures S1 and S2. embryos suggest that the E203K substitution results in the most active MEK, based on the severity of disruptions to ERK-dependent morphogenetic processes [21, 32]. For example, using ectopic veins in fly wings as an indicator for ERK pathway overactivation, Jindal et al. [32] found that E203K causes a phenotype that is much stronger than are the phenotypes caused by the F53S and Y130C variants ( Figure 3B ). Can these phenotypic differences be attributed to corresponding changes in the kinetic parameters of the mutant enzymes?
Our analysis of E203K MEK kinetic data ( Figure S4 ) revealed that the catalytic efficiency of the first phosphorylation step is indeed strongly increased for E203K MEK, almost 2-fold when compared with the wild-type enzyme ( Figures 3C and 3E ). This increase is accompanied by a pronounced reduction in the efficiency of the second phosphorylation step and a dramatic increase of processivity, indicating that more than half of ERK molecules are dually phosphorylated by the same enzyme. Thus, the processivity of MEK can be increased not only by crowded conditions and scaffolding proteins, as was suggested by earlier studies [37, 38], but also by activating mutations (Figures 3C  and 3E) . Notably, however, the E203K mutation did not affect the ordering of the dual phosphorylation mechanism (Figures S3A-S3C).
In contrast to the effects observed for E203K, kinetic parameters of ERK phosphorylation by the F53S and Y130C variants remain largely unchanged from the wild-type MEK ( Figures  3C, 3F , 3G, and S4). This is puzzling, as these mutants show clear phenotypes in vivo and are associated with diseases ( Figure 3B ). To test if the phenotypic effects stem from changes in other processes, such as the activation of MEK itself, we analyzed the kinetics of MEK phosphorylation by Raf. This analysis revealed that both F53S and Y130C are activated significantly more quickly than wild-type MEK are ( Figure 4 ). Interestingly, the activation kinetics of E203K MEK are indistinguishable from those of the wild-type MEK. Thus, our analysis reveals which of the multiple processes involved in multisite phosphorylation are affected by each mutation.
Together, this study takes a step toward closing the gap between work with purified signaling enzymes and their effects in the living organism. In particular, it has been proposed that distributive regime of ERK phosphorylation by MEK plays a key role in the emergence of switchlike responses in larger biochemical networks that contain the ERK phosphorylation reaction [42] [43] [44] [45] . Our results establish that both distributive and processive pathways must be considered in analyzing the emergence of these systems-level effects for both wild-type enzymes and their pathogenic variants. While kinetic parameters may be estimated using a wide variety of approaches [46], we used model reduction and Bayesian inference, because they are well suited to our particular goals of systematic comparison of MEK variants. Specifically, our attempts to estimate parameters of the original model failed to constrain the values of individual rate constants and identified a large ensemble of six-dimensional parameter vectors that provide equivalent fit to data ( Figure S2A ). Importantly, the values of the effective parameters computed on the basis of this ensemble were highly constrained, which gave us the ability to compare the kinetics of the various MEK mutants using Bayesian inference with the analytically solvable reduced model. We expect that rationally reduced models will continue to play a key role in establishing a deeper understanding of cell regulation systems, including their quantitative responses to mutations of constituent proteins.
STAR+METHODS
Detailed methods are provided in the online version of this paper and include the following: 
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Figure 4. Quantification of MEK Activation by Raf via Western Blot
Raf activates the F53S and Y130C variants more quickly than it activates the wild-type MEK and the E203K variant. The normalized dually phosphorylated (dp) MEK signal is an average of three experimental replicates, and the error bars represent the standard error of the mean. 1.50mg/mL ± 0.05mg/mL by determining the A280 using Nanodrop (Thermo Scientific Nanodrop lite) with an extinction coefficient of 42230 cm -1 M -1 . 25mL aliquots were flash-frozen using liquid N 2 and stored at À80 C until use. Human His 6 -MEK variants were expressed in E. coli BL21 DE3 cells supplemented with 50 mg/uL Kanamycin and purified using the same procedure as described above except that the MEK variants were determined to be 0.50mg/mL ± 0.05mg/mL by determining the A280 using Nanodrop with an extinction coefficient of 23620 cm -1 M -1 . All protein measurements were expressed as mean ± SD from 4 measurements. All exctinction coefficeints were calcualted using the protein sequence and Northwestern Center for Biotechnology's Peptide Property Calculator.
METHOD DETAILS ERK phosphorylation by MEK
To prepare activated MEK, 6.5mM of MEK was added to a master mix containing the phosphorylation buffer, 5mM ATP, and 0.05mM of active human c-Raf (Millipore). The reaction mixture was incubated at 30 C for 1.5 h. To ensure that MEK was fully activated, we took aliquots throughout the 1.5 h and ran the samples using phos-tag gel electrophoresis as described below to ensure that the nonphosphorylated form had fully disappeared. We performed Western Blot against dually phosphorylated MEK (1:4000 dilution, Cell Signaling Technology, Cat#9121, RRID: AB_331648) with Alexa Fluor 647 conjugates as the secondary antibody (1:2000 dilution, Invitrogen Cat#A-31573, RRID: AB_2536183) to ensure complete phosphorylation. To initiate the MEK-ERK reaction, 0.67mM of activated MEK was then added to a master mix containing phosphorylation buffer, 5mM ATP, and 5mM ERK. The enzyme to substrate ratio was chosen to ensure that the reaction ran to completion within a reasonable time frame. Time points were chosen to best capture the dynamics of the peak concentration of the monophosphorylated form. Time point samples were collected by adding 4uL of the reaction to 1.5uL of 4x SDS loading buffer (250mM Tris-HCl pH 6.8, 10% SDS, 0.01% bromophenol blue, 40% glycerol, 2.86M b-mercaptoethanol) at 0.0, 0.5, 2.0, 3.3, 3.7, 5.0, 10.0, and 20.0 min. The samples were heated at 60 C for 10 min. For phosphomimetic MEK (S218D,S222D MEK), 2.5mM of phosphomimetic MEK was added and aliquots were taken out at 0.0, 1.0, 2.0, 3.3, 5.0, 10.0, 20.0, and 40.0 min.
Phos-tag gel 5uL of each sample was loaded onto Wako SuperSep Phos-tag 12.5% 17 well gel (Wako, Cat#195-17991) and ran at 175V for 160 min with Tris/Glycine/SDS running buffer (Bio-Rad). To visualize the gel bands, the gel was stained with Coomassie R staining solution (0.05% w/v Coomassie Brilliant Blue R, 25% isopropanol and 10% acetic acid) for 30 min before destaining with 10% acetic acid until the bands were clearly visible. The phos-tag gels were imaged using the Bio-Rad ChemiDoc MP Imaging System. The intensities of the bands were quantified using ImageJ's (ImageJ, RRID: SCR_003070) 'gels' tool to measure the area of the peak.
MEK activation by Raf-1 0.05mM of active human c-Raf (Millipore) was added to 6.5mM of MEK in the phosphorylation buffer containing 5mM ATP. The reaction mixture was incubated in a 30 C water bath and 4mL aliquots were taken at 0.0, 1.0, 2.5, 5.0, 10.0, 20.0 and 40.0 min and added to 1.5mL of 4x SDS loading buffer to quench the reaction. The samples were heated at 60 C for 10 min to break the disulfide bonds. 5mL of each sample was loaded onto a 15-well Any kD Mini-PROTEAN TGX Precast Protein Gel (Bio-Rad) and ran at 200V for 45 min. The proteins were transferred onto a TransBlot Turbo LF PDVF membrane (Bio-Rad) using the TransBlot Turbo system (Bio-Rad). The membrane was then pre-incubated in 4% w/v milk powder in PBST (1x PBS + 0.1% Tween-20) for one h. The membrane was then incubated in 4% milk containing primary antibody against dually phosphorylated MEK (1:4000 dilution, Cell Signaling Technology) overnight. After three 15-min washes in PBST, the membrane was switched into 4% milk containing the secondary antibody donkey Alexa Fluor 647 anti-rabbit conjugate (1:2000 dilution, Invitrogen) for 1 h. After another three 15-min washes in PBST, the membrane was imaged using the Bio-Rad ChemiDoc MP Imaging System. The intensities of the bands were quantified using ImageJ's 'gels' tool to measure the areas under the peaks.
Phosphorylation ratio by mass spectrometry
From a reaction of ERK phosphorylation by activated MEK E203K, 20mL of sample was collected at 3 min 15 s. The reaction was stopped by adding the sample to 60 mL 10M Urea. To remove salts and glycerol, a TCA precipitation was performed with the following procedure: 8 mL of chilled 0.15% N-Laurylsarcosine sodium and 8 mL of chilled 100% TCA were added to the sample on ice and mixed by inverting the tube a few times. After 15 min, the sample was centrifuged at 4 C for 10 min and the supernatant was removed. 0.4mL of 100% methanol was added and the solution was vortexed for 10 s. The supernatant was removed after centrifugation and another 0.4mL of 100% methanol was added, the solution vortexed, centrifuged and the supernatant removed. The resulting protein pellet was air-dried and subsequently resolubilized in 10 mL of 6M guanidine hydrochloride (GuHCl).
Synthetic AQUA peptides were ordered from JPT Peptide Technologies. These peptides have heavy arginine incorporated (+10.00826859 Da) and correspond to the tryptic peptides of the pY-phosphorylated, and the pT-phosphorylated forms of ERK. 3uL of each AQUA (14mM in HPLC water) was added to the sample and the sample was diluted to 2M GuHCl with 10mM EPPS pH 8.5 and digested overnight at 22 C with 10ng/ mL LysC (Wako, 2mg/ mL stock in HPLC water). The next morning, the sample was further diluted to 0.5M GuHCl with 10mM EPPS pH 8.5 and an additional 10ng/ mL LysC and 20 ng/ mL Trypsin (Promega) were added. The sample was incubated overnight at 37 C. All solvent was removed in vacuo and resuspended in 5% phosphoric acid. To desalt, stage-tip was performed, and the sample was resuspended in 40 mL 10% TFE, 1% TCA. 1mL was analyzed by LC-MS.
The Orbitrap Fusion Lumos (Thermo Fisher) was coupled with an Easy nLC 1200 high pressure liquid chromatography HPLC (Thermo Fisher) with an autosampler. For each run, injected peptides were separated on a 100mm inner diameter microcapillary column with $0.5cm of 5mm BEH C18 beads (Waters) and 30cm of $1.7mm BEH C18 beads (Waters). A 16%-36% ACN gradient in 0.125% formic acid and 2% DMSO was applied over 40 min at 350nL/min. Ion transfer tube was maintained at 300 C and electrospray ionization was enabled by applying a voltage of 2.6 kV through a microtee at the inlet of the microcapillary column. The mass spectrometer was operated in data dependent mode with a survey scan using the Orbitrap at a resolution setting of 120k with a scan range of 500 -850 m/z with an RF Lens (%) of 30, AGC target of 1.0E6 and a maximum injection time of 100 ms. Charge states between 2+ and 6+ were included. A dynamic exclusion window of 5 s with a mass tolerance of ± 10 ppm was used. Peptides were fragmented using 30% HCD collision energy. MS2 spectrum was acquired using the Orbitrap at a resolution of 15k with an AGC target of 5.0e4 and a maximum injection time of 250 ms.
The Gygi Lab GFY software licensed from Harvard was used to convert mass spectrometric data from the Thermo RAW file to the mzXML format, and to correct erroneous assignments of peptide ion charge state and monoisotopic m/z. We used RawFileReader libraries from Thermo, version 4.0.26 to convert the raw files into mzXML file format. Assignment of MS2 spectra was performed using the SEQUEST algorithm by searching the data against the appropriate proteome reference dataset acquired from UniProt (Homo sapiens with Proteome ID UP000005640, Organism ID 9606, Protein count 74349; Escherichia coli (strain K12) with Proteome ID UP000000625, Organism ID 83333, Protein count 4391; both downloaded in June,2017) including 114 common contaminants like human Keratins and Trypsin [51, 52] . The target-decoy strategy was used to construct reversed sequences in order to estimate the false discovery rate on the peptide level [53] . SEQUEST searchers were performed using a 20ppm precursor ion tolerance where both N and C-termini were required to be consistent with the protease specificity of Lys-C and Trypsin. Fragment ion tolerance in the MS2spectrum was set at 0.02 Th. N-ethyl maleimide (+125.047679 Da) was set as a static modification on cysteine residues. Oxidation of methionine (+ 15.99492 Da), heavy arginine (+10.00826859 Da), and phosphorylation at serine, tyrosine, and threonine (+79.9663304104 Da) were set as variable modifications. A peptide level MS2 spectral assignment false discovery rate (FDR) of 0.5% was obtained by applying the target decoy strategy with linear discriminant analysis. The linear discriminant analysis used the following features: SEQUEST parameters XCorr and DXCorr, charge state, peptide length and absolute peptide mass accuracy. Forward peptides within three standard deviation of the theoretical m/z of the precursor were used as the positive training set. All reverse peptides were used as the negative training set. Peptides of at least seven amino acids were rank ordered by linear discriminant analysis score and were filtered to the desired cutoff. Peptides were assigned to proteins and filtered with 0.5% FDR on the protein level using the ''picked'' protein FDR approach [54] . Protein redundancy was removed by assigning peptides to the minimal number of proteins which can explain all observed peptides.
The elution profiles of the pT and the pY tryptic peptides were extracted using Xcalibur Qual Browser (Thermo), focusing on the base peak with m/z of range 741.99-742.00 (sample) and 745.32-745.34 (AQUA). The 3+ tryptic peptide of the mono phosphorylated ERK has a theoretical m/z of 741.99507 and the corresponding AQUA with heavy arginine has a theoretical m/z of 745.33116. The extracted information was processed in Excel (Microsoft). Despite an equal amount of the pY-and pT-phosphorylated AQUA were spiked into the sample, the two peptides have different detection signal because of their difference in flyability. We therefore normalized the peak intensity of the sample to the corresponding maximum peak intensity of the AQUA and smoothen the chromatogram by taking the 5-point moving average. The area under the curve for each of the four peaks was calculated using the trapezoidal method and the ratio between the sample and the AQUA calculated for both the pT-and the pY-phosphorylated peptides. The MS2 spectrum corresponding to the pY-and the pT-phosphorylated peptides with labeled information were extracted using the SuperDig tool from the Gygi Lab GFY software. The mass spectrometry proteomics data have been deposited to the ProteomeXchange Consortium via the PRIDE partner repository with the dataset identifier PXD016580 [47, 55]. To simplify notation, we introduce k 1 = E tot k cat;1 =K M;1 , k 2 = E tot k cat;2 =K M;2 , and p = k cat;2 =ðk r;2 + k cat;2 Þ. Equations 9, 10, and 11 become:
Kinetic modeling
)
and have the following solutions:
Identifiability
To determine if the parameter values of the reduced model (Equations 12, 13, and 14) could be recovered from data, we tested their structural identifiability using the time course data consisting of multiple trials of the measurable output ðS 0 ;S 1 ;S 2 Þ. A model is structurally identifiable if there is a subset of the parameter space such that any parameter can be uniquely determined from noise-free measurable output. Establishing structural identifiability is a first step before inferring parameters. We found that the model is structurally identifiable using the differential algebra method [48] as implemented in the software DAISY [49].
Bayesian parameter inference
This posterior distribution is proportional to the likelihood times the prior distribution of the parameters before any data is observed. We assumed that the distribution of the given measurements is governed by Equations 15, 16, and 17 convoluted with Gaussian white noise. Thus, we infer k 1 , k 2 , and p, the three parameters in Equations 15, 16, and 17, and the standard deviation s, which is constant across observations. Measurements of the three states, S Ã 0 ;S Ã 1 and S Ã 2 , are taken from n different replicates at 7 time points, so our sample space is X = R 3Ã7Ãn for each of the MEK variants; the number of replicates was equal to 12 for wild type MEK and 5 for MEK variants with phosphomimetic or activating mutations.
If S is the analytic solution of Equations 15, 16, and 17, a three dimensional real vector depending on the parameters, as well as on time t, gives rise to the likelihood via ðS Ã 0 ; S Ã 1 ; S Ã 2 Þ t;i $ N ðSðk 1 ;k 2 ;p;tÞ;s 2 I 3 Þ, where i indicates the replicate of the measurement, N denotes the multivariate normal distribution with mean vector Sðk 1 ; k 2 ; p; tÞ and covariance matrix s 2 I 3 . We chose the prior distributions, k 1 , k 2 , s $ Unifð0; 10Þ, and p $ Unif ð0; 1Þas p can only take parameters in this range.
We used PyStan distribution of the STAN software for Bayesian Analysis [50] , which allows us to sample approximately from the posterior distributions using Markov Chain Monte Carlo methods. In our implementation, we used four chains with 500 warm-up draws and 500 post-warm-up draws, respectively.
QUANTIFICATION AND STATISTICAL ANALYSIS
MATLAB version R2016a was used for least-squares fitting. The differentiable algebra method using the software DAISY was used to verify that the model is structurally identifiable [48, 49] . The reduced ODE model is described in detail in the Reduced model section of the Method Details. Priors and likelihood of Bayesian inference are described in detail in the Bayesian parameter inference section of the Method Details. PyStan version 2.19 distribution of the statistical software STAN was used to access information on the posterior distribution via approximate sampling. STAN used Hamiltonian Markov Chain Monte Carlo to approximately sample from the posterior distribution. In total, N = 2000 samples were drawn from four Markov chains. Each sample is a four dimensional real vector, containing the three biological parameters and the standard deviation of the Gaussian noise, denoted s. From each chain, 500 warm-up draws were performed and discarded before drawing 500 further samples, which we then analyzed. For each of the four mutant MEK variants, we checked that the chains were sufficiently burnt in after the warmup phase by looking at trace plots and output statistics, in particular, the Rhat parameter and the effective sample size estimates. The resulting histograms for the marginal distributions of the three parameters of interest in are shown Figure 3D .
The parameter means reported by PyStan are as follows:
Error bar definitions can be found in figure legends. The number of experimental replicates for the dual phosphorylation of ERK by wild type MEK is reported in the legend of Figure 1 . The number of experimental replicates for the dual phosphorylation of ERK by the four mutant MEK variants is reported in the Bayesian parameter inference section of the Method Details. The number of experimental replicates for the phosphorylation of monophosphorylatable ERK by wild type MEK is reported in the legend of Figure S1 . The number of experimental replicates for the activation of MEK by Raf is reported in the legend of Figure 4 .
DATA AND CODE AVAILABILITY
Least-squares fitting was performed using the lsqcurvefit routine in MATLAB version R2016a with the objective function described in the legend of Figure S2 . Bayesian parameter inference was performed using PyStan version 2.19 distribution using Hamiltonian Markov Chain Monte Carlo methods with the details described in the Method Details. The mass spectrometry data for the phosphorylation ratio of ERK is available via ProteomeXchange with identifier PXD016580 [47]. 
